Last update April 22, 2026

Drospirenone

Compatible

Safe product and/or breastfeeding is the best option.

It is a progestogen analog of spironolactone with antiandrogenic activity. Used as a contraceptive. Oral administration.

It is excreted in breast milk in a clinically insignificant amount and no problems have been reported in infants whose mothers took it. (Melka 2020, Blode 2001) 

The manufacturing laboratory considers it compatible with breastfeeding. (AEMPS 2019, FDA 2019)

For a detailed discussion with references:

  • on why non-hormonal methods are the first choice during the first 4–6 weeks postpartum, followed by IUDs and progestin implants,
  • on the potential problems associated with the use of combined estrogen-progestin contraceptives,
  • the possible decrease in milk production with estrogen use,
  • and why progestin-only contraceptives are preferable during breastfeeding,

see below: “(Combined Estrogen + Progestin Contraceptives, COCs)”


See below the information of these related products:

Alternatives

We do not have alternatives for Drospirenone since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Drospirenone in other languages or writings:

Group

Drospirenone belongs to this group or family:

Tradenames

Main tradenames from several countries containing Drospirenone in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 76 %
Molecular weight 367 daltons
Protein Binding 97 %
VD 4 l/Kg
pKa 18.5 -
Tmax 3 - 4 hours
T½ 32 hours
M/P ratio 0.17 -
Theoretical Dose 0.0005 (0.0002 -0.001) mg/Kg/d
Relative Dose 1.1 (0.4 - 2.1) %

References

  1. Melka D, Kask K, Colli E, Regidor PA. A single-arm study to evaluate the transfer of drospirenone to breast milk after reaching steady state, following oral administration of 4 mg drospirenone in healthy lactating female volunteers. Womens Health (Lond). 2020 Jan-Dec;16:1745506520957192. Abstract
  2. AEMPS. Exeltis. Drospirenona (Slinda). Ficha técnica. 2019 Full text (in our servers)
  3. FDA-Exeltis. Drospirenona(Slynd)-DS Drug Summary. 2019 Full text (in our servers)
  4. Blode H, Foidart JM, Heithecker R. Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women. Eur J Contracept Reprod Health Care. 2001 Sep;6(3):167-71. Abstract

Total visits

47,080

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Instituto de Salud Infantil, Grecia-Institute of Child´s Health in Greece

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM